HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herholz, K. Articles by Ebmeier, K. Search for Related Content PubMed PubMed Citation Articles by Herholz, K. Articles by Ebmeier, K.

Direct Comparison of Spatially Normalized PET and SPECT Scans in Alzheimer’s Disease

¹ Neurologische Universitätsklinik, Köln, Germany
² Max-Planck-Institut für neurologische Forschung, Köln, Germany
³ Nuklearmedizinische Universitätsklinik, Köln, Germany
⁴ Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom

Hexamethylpropyleneamine oxime (HMPAO) SPECT and ¹⁸F-FDG PET depict similar aspects of perfusion and metabolic abnormalities in Alzheimer’s disease (AD), but the correspondence between them is not known in detail. We therefore used statistical parametric mapping to detect and compare abnormal brain areas objectively and quantitatively. Methods: Twenty-six patients with probable AD (mean age ± SD, 66 ± 9 y; mean Mini-Mental State Examination score, 22.5 ± 4.2) and 6 nondemented healthy volunteers (mean age, 63 ± 11 y) were studied with HMPAO SPECT and ¹⁸F-FDG PET. All images underwent the same processing steps, including 12-mm gaussian smoothing, spatial normalization, and z transformation with respect to normal average and SD. Thresholding of z maps was used to detect abnormal voxels. Results: The overall correlation between PET and SPECT across the entire brain was significant but not close (average r = 0.43). The best correspondence was found in the temporoparietal and posterior cingulate association cortices. There, the number of abnormal voxels for PET correlated strongly with the number for SPECT (r = 0.90 at a z threshold of -2.25), but tracer uptake reductions were significantly more pronounced for PET than for SPECT. Discordant findings were most frequently seen in the temporobasal and orbitofrontal areas (PET low, SPECT high) and in the cerebellum, parahippocampal cortex, and midcingulate cortex (PET high, SPECT low). The correlation between dementia severity and the number of abnormal voxels was closer for PET than for SPECT. Separation of patients from healthy volunteers by counting the number of abnormal voxels was possible over a much wider range of z thresholds with PET than with SPECT. Conclusion: Correspondence between ¹⁸F-FDG PET and HMPAO SPECT is limited to the main finding of temporoparietal and posterior cingulate functional impairment in mild to moderate AD. The distinction between healthy volunteers and patients is less sensitive to threshold selection with PET than with SPECT, and findings in the frontal, temporobasal, and temporomesial cortices and in the cerebellum may differ between the 2 techniques.

Key Words: PET • SPECT • Alzheimer’s disease • ^99mTc-HMPAO • ¹⁸F-FDG

This article has been cited by other articles:

				S L PIMLOTT and K P EBMEIER SPECT imaging in dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S153 - S159. [Abstract] [Full Text] [PDF]

				K HERHOLZ, S F CARTER, and M JONES Positron emission tomography imaging in dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S160 - S167. [Abstract] [Full Text] [PDF]

				H. Matsuda Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT J. Nucl. Med., August 1, 2007; 48(8): 1289 - 1300. [Abstract] [Full Text] [PDF]

				H. Matsuda, S. Mizumura, T. Nagao, T. Ota, T. Iizuka, K. Nemoto, N. Takemura, H. Arai, and A. Homma Automated Discrimination Between Very Early Alzheimer Disease and Controls Using an Easy Z-Score Imaging System for Multicenter Brain Perfusion Single-Photon Emission Tomography AJNR Am. J. Neuroradiol., April 1, 2007; 28(4): 731 - 736. [Abstract] [Full Text] [PDF]

				D. H.S. Silverman Brain 18F-FDG PET in the Diagnosis of Neurodegenerative Dementias: Comparison with Perfusion SPECT and with Clinical Evaluations Lacking Nuclear Imaging J. Nucl. Med., April 1, 2004; 45(4): 594 - 607. [Abstract] [Full Text] [PDF]

				T. Yoshikawa, K. Murase, N. Oku, M. Imaizumi, M. Takasawa, P. Rishu, Y. Kimura, Y. Ikejiri, K. Kitagawa, M. Hori, et al. Heterogeneity of Cerebral Blood Flow in Alzheimer Disease and Vascular Dementia AJNR Am. J. Neuroradiol., August 1, 2003; 24(7): 1341 - 1347. [Abstract] [Full Text] [PDF]

				B. Matthews, E. R. Siemers, and P. D. Mozley Imaging-Based Measures of Disease Progression in Clinical Trials of Disease-Modifying Drugs for Alzheimer Disease Am J Geriatr Psychiatry, April 1, 2003; 11(2): 146 - 159. [Abstract] [Full Text] [PDF]

				T. Yoshikawa, K. Murase, N. Oku, K. Kitagawa, M. Imaizumi, M. Takasawa, T. Nishikawa, M. Matsumoto, J. Hatazawa, and M. Hori Statistical Image Analysis of Cerebral Blood Flow in Vascular Dementia with Small-Vessel Disease J. Nucl. Med., April 1, 2003; 44(4): 505 - 511. [Abstract] [Full Text] [PDF]

				J. Neugroschl and K. L. Davis Biological Markers in Alzheimer Disease Am J Geriatr Psychiatry, December 1, 2002; 10(6): 660 - 677. [Abstract] [Full Text] [PDF]